1961•Archives of OphthalmologyRequires access

Tropicamide as a Cycloplegic Agent

Ben Milder

Open publisher page 33 citations

Abstract

The importance of cycloplegia in refraction is attested to by the continuing search for the ideal cycloplegic drug. This ideal drug should provide (1) maximum relaxation of accommodation; (2) satisfactory mydriasis; (3) rapid onset of action and rapid attainment of maximum effect; (4) short duration and rapid recovery; (5) consistency in its effectiveness; (6) freedom from toxicity, irritation, or sensitivity. For many decades, homatropine was the drug of choice for cycloplegia in refraction. Several newer drugs have far surpassed homatropine in all of the above qualifications except one. Unfortunately that one is the first and most important of all—maximum cycloplegic effect1! The search goes on. Recently, tropicamide * has claimed the attention of investigators and clinicians. Tropicamide is a parasympatholytic drug (N-ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide). It was introduced on the European continent, and has been reported on recently in the American literature.2,3Merrill et al.,2in a study of 262 patients

About this research paper

What this paper is about

The importance of cycloplegia in refraction is attested to by the continuing search for the ideal cycloplegic drug. This ideal drug should provide (1) maximum relaxation of accommodation; (2) satisfactory mydriasis; (3) rapid onset of action and rapid attainment of maximum effect; (4) short duration and rapid recovery; (5) consistency in its effectiveness; (6) freedom from toxicity, irritation, or sensitivity. For many decades, homatropine was the drug of choice for cycloplegia in refraction. Several newer drugs have far surpassed homatropine in all of the above qualifications except one. Unfortunately that one is the first and most important of all—maximum cycloplegic effect1! The search goes on. Recently, tropicamide * has claimed the attention of investigators and clinicians. Tropicamide is a parasympatholytic drug (N-ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide). It was introduced on the European continent, and has been reported on recently in the American literature.2,3Merrill et al.,2in a study of 262 patients

Why it matters

OpenAlex reports 33 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The importance of cycloplegia in refraction is attested to by the continuing search for the ideal cycloplegic drug. This ideal drug should provide (1) maximum relaxation of accommodation; (2) satisfactory mydriasis; (3) rapid onset of action and rapid attainment of maximum effect; (4) short duration and rapid recovery; (5) consistency in its effectiveness; (6) freedom from toxicity, irritation, or sensitivity. For many decades, homatropine was the drug of choice for cycloplegia in refraction. Several newer drugs have far surpassed homatropine in all of the above qualifications except one. Unfortunately that one is the first and most important of all—maximum cycloplegic effect1! The search goes on. Recently, tropicamide * has claimed the attention of investigators and clinicians. Tropicamide is a parasympatholytic drug (N-ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide). It was introduced on the European continent, and has been reported on recently in the American literature.2,3Merrill et al.,2in a study of 262 patients

Key concepts: Tropicamide, Cycloplegia, Medicine, Mydriasis, Mydriatics, Optometry, Drug, Irritation

Related papers

Back to paper searchBrowse research topicsOriginal source
Tropicamide as a Cycloplegic Agent — Research Paper | ScholarLens